226 related articles for article (PubMed ID: 24997850)
1. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study.
Reimers MS; Engels CC; Putter H; Morreau H; Liefers GJ; van de Velde CJ; Kuppen PJ
BMC Cancer; 2014 Jul; 14():486. PubMed ID: 24997850
[TBL] [Abstract][Full Text] [Related]
2. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients.
Zeestraten EC; Reimers MS; Saadatmand S; Goossens-Beumer IJ; Dekker JW; Liefers GJ; van den Elsen PJ; van de Velde CJ; Kuppen PJ
Br J Cancer; 2014 Jan; 110(2):459-68. PubMed ID: 24196788
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Engels CC; Charehbili A; van de Velde CJ; Bastiaannet E; Sajet A; Putter H; van Vliet EA; van Vlierberghe RL; Smit VT; Bartlett JM; Seynaeve C; Liefers GJ; Kuppen PJ
Breast Cancer Res Treat; 2015 Feb; 149(3):587-96. PubMed ID: 25616355
[TBL] [Abstract][Full Text] [Related]
4. Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancer.
Ishigami S; Arigami T; Uenosono Y; Matsumoto M; Okumura H; Uchikado Y; Kita Y; Nishizono Y; Maemura K; Kijima Y; Nakajo A; Owaki T; Ueno S; Hokita S; Natsugoe S
Cancer Immunol Immunother; 2012 Oct; 61(10):1663-9. PubMed ID: 22374482
[TBL] [Abstract][Full Text] [Related]
5. HLA class I expression and its alteration by preoperative hyperthermo-chemoradiotherapy in patients with rectal cancer.
Sato H; Suzuki Y; Ide M; Katoh T; Noda SE; Ando K; Oike T; Yoshimoto Y; Okonogi N; Mimura K; Asao T; Kuwano H; Nakano T
PLoS One; 2014; 9(9):e108122. PubMed ID: 25259797
[TBL] [Abstract][Full Text] [Related]
6. Immunoregulatory function of HLA-G in gastric cancer.
Tuncel T; Karagoz B; Haholu A; Ozgun A; Emirzeoglu L; Bilgi O; Kandemir EG
Asian Pac J Cancer Prev; 2013; 14(12):7681-4. PubMed ID: 24460353
[TBL] [Abstract][Full Text] [Related]
7. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
9. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer.
de Kruijf EM; van Nes JG; Sajet A; Tummers QR; Putter H; Osanto S; Speetjens FM; Smit VT; Liefers GJ; van de Velde CJ; Kuppen PJ
Clin Cancer Res; 2010 Feb; 16(4):1272-80. PubMed ID: 20145162
[TBL] [Abstract][Full Text] [Related]
10. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
[TBL] [Abstract][Full Text] [Related]
11. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment Mediators CD8
Zaghloul H; Abbas A; Abdulah D
J Gastrointest Cancer; 2021 Mar; 52(1):177-186. PubMed ID: 32112202
[TBL] [Abstract][Full Text] [Related]
13. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.
Schnellhardt S; Hirneth J; Büttner-Herold M; Daniel C; Haderlein M; Hartmann A; Fietkau R; Distel L
Front Immunol; 2022; 13():781222. PubMed ID: 35140715
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
16. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients.
de Kruijf EM; Sajet A; van Nes JG; Natanov R; Putter H; Smit VT; Liefers GJ; van den Elsen PJ; van de Velde CJ; Kuppen PJ
J Immunol; 2010 Dec; 185(12):7452-9. PubMed ID: 21057081
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma.
Vangangelt KMH; van Pelt GW; Engels CC; Putter H; Liefers GJ; Smit VTHBM; Tollenaar RAEM; Kuppen PJK; Mesker WE
Breast Cancer Res Treat; 2018 Apr; 168(3):601-612. PubMed ID: 29273955
[TBL] [Abstract][Full Text] [Related]
19. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
[TBL] [Abstract][Full Text] [Related]
20. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
